Does anyone recall in the BoM findings if B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP) measurements were significantly reduced or improved in any of the patients, particularly those with CHF?

Also, narmac I think you are bang on. Even if a significant partner is announced for BoM2 it will only have a modest impact on share price unless RVX is listed and promoted on NAZDAQ. Just my opinion. GLTA.

Thanks

Toinv